Over the past forty years, there has been a great advance in antiviral infections treatment. The discovery of acyclovir in 1977 paved the way to new antiviral drugs. Other nucleoside analogues such as valacyclovir, penciclovir, famciclovir, ganciclovir, valganciclovir, cidofovir and foscarnet were made available, as well as neuraminidase inhibitors. Also, drugs for the treatment of viral hepatitis and patients with HIV/AIDS have not only increased life quality and expectancy, but also decreased the incidence of some viral infections. Antiviral drugs are important tools to the clinician, especially when treating patients with impaired immunological and clinical condition. Aiming to restore health and prevent further adverse events, the clinician must be aware of the best antiviral drug available, its proper route of administration and dosage. The aim of this review is to present the antiviral drugs currently available, focusing on treatment of common viral infections in clinical practice. A brief description of the mechanisms of action and prescription of antiviral drugs is presented, using the data available from evidence-based medicine.
INTRODUCTION
Despite the impact of viral infections on human health, there is still a mismatch when the development of antiviral drugs is compared to other antimicrobial agents, a fact that can be observed by the restricted options of antiviral drugs available for use. Knowing that the goal of an antiviral chemotherapy is the use of antiviral agents that specifically inhibit viral multiplication without affecting normal cell division, the choice of an optimal drug must also rely on patients' age and their immunological and clinical status. People with chronic medical conditions (including obesity), children younger than 2 years old, patients with 65 years old or older, and pregnant women may be at an increased risk for complications of viral infections.
This manuscript provides information on antiviral treatment for herpes simplex (HSV), varicella zoster (VZV), influenza and cytomegalovirus (CMV) infections.
This information will help clinicians prescribe antiviral drugs to the viral infections described here. The purpose of this review is to present an update on antiviral drugs currently available, focusing on treatment of common viral infections in clinical practice, presenting a brief description of antiviral mechanisms of action in order to guide drug prescription, using the data available from evidence-based medicine.
Seeking not to be repetitive, and especially not incurring in contradictory information to official guidelines available for the treatment of HIV, hepatitis B and C infections, we chose not to address this issue by providing in the list of references the links to access these therapeutic protocols provided by the Brazilian Ministry of Health (Brasil, 2013; Brasil, 2015) .
ANTIVIRAL DRUGS

Nucleoside Analogues
In 1977, Gertrude Elion and colleagues discovered acyclovir (ACV), a synthetic drug that was a turning point in antiviral therapy (Elion et al., 1977) . ACV (9-[-2-hydroxymethyl]guanine) is a synthetic purine analogue that is obtained by molecular simplification or through the opening of the guanosine ring ( Figure 1 ). It is an effective drug against herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella zoster virus (VZV), with an excellent safety profile. Other nucleoside analogues were subsequently discovered such as valacyclovir (VACV), penciclovir (PCV), famciclovir (FCV), ganciclovir (GCV) and valganciclovir (VGCV) (Figure 1 ). 
Acyclovir and Valacyclovir
After intracellular uptake, virally encoded thymidine kinase (TK) converts ACV to acyclovir monophosphate (ACV-MP), which is subsequently converted to acyclovir triphosphate by cell enzymes (ACV-TP) (Figure 2A) .
Once ACV-TP is a deoxyguanosine triphosphate analogue (dGTP), it competitively inhibits viral DNA polymerase. Incorporation of ACV-TP molecule into DNA results in chain termination since the absence of a 3'hydroxyl group prevents the attachment of additional nucleosides ( Figure  2A ). The ACV-TP molecule has a much higher affinity for viral DNA polymerase than for its cell homologue, yielding a high therapeutic ratio (Whitley & Gnann, 1992) .
Valacyclovir (VCV) is the L-valyl ester and a pro-drug of the antiviral drug acyclovir. It is converted, in vivo, to ACV, which is then phosphorylated to ACV-TP and irreversibly binds to viral DNA polymerase, effectively inactivating the enzyme (Pier et In decreasing order of susceptibility, ACV and VCV are active against HSV types 1 and 2 (HSV-1, HSV-2), VZV and Epstein-Barr (EBV) viruses (Whitley & Gnann, 1992) . ACV is inactive against cytomegalovirus (CMV), which does not encode thymidine kinase (TK). The ACV activity against HSV types 6, 7 and 8 is not well defined . Although active against EBV, VCV is not usually clinically recommended for EBV infections .
Mechanisms of resistance to ACV and VCV are rarely reported in immunocompetent patients and occur by (i) reduced or absent thymidine kinase, (ii) altered thymidine kinase activity resulting in decreased ACV phosphorylation or (iii) altered viral DNA polymerase with decreased affinity for ACV-TP (Perrier et al., 2016) .
Usually, ACV resistance is linked to mutations in viral TK, while mutations in viral DNA polymerase are rare. In most cases, altered viral TK does not present enzymatic activity and the HSV responsible for the infection is referred to as TK-negative phenotype. TK-negative types also present cross-resistance to famciclovir (FCV) and, although being capable of latency, they are deficient to reactivate. It is suggested that recurrences are most often associated with a drug-sensitive strain. Sometimes, ACV resistance is due to a TK with altered substrate specificity, which can or cannot show resistance to FCV (Boyd et al., 1993) .
However, it is noteworthy that the resistance phenomenon is rare in immunocompetent hosts and that therapy failure is usually a result of the delay in initiating antiviral therapy, reduced drug absorption or lack of adherence to treatment. Even in immunocompromised hosts, HSV resistance to nucleoside analogues is lower than 1%, and it is mainly observed in those patients under prolonged therapy (Piret & Boivin, 2011) . Confirmation of HSV resistance to ACV or VCV requires genotypic and phenotypic tests and the treatment for ACV-resistant infections is usually done with foscarnet, a pyrophosphate analogue, or with cidofovir, an acyclic analogue of cytosine (Erlich et al., 1989; Hardy, 1992; .
ACV oral bioavailability is about 15 to 30%, which decreases at higher doses. Since intravenous administration yields higher plasma concentrations than oral doses, it should be used for serious infections such as disseminated varicella in immunocompromised hosts .
VCV has three-to five-fold greater oral bioavailability than ACV and food does not affect its absorption (Zachary, 2014a ). Intravenous ACV generates higher peak levels than oral VCV. However, it may also increase the risk of renal toxicity due to precipitation of ACV crystals in renal tubules (Perry & Faulds, 1996; Zachary, 2014a) . On the other hand, the safety of highdose oral VCV remains controversial, especially in immunocompromised patients (Zachary, 2014a) .
The management of pregnant women with symptomatic genital herpes should be done in consultation with infectious diseases/sexual health and obstetric specialists simultaneously. ACV and VCV have been assigned to Pregnancy Category B, and ACV has been used in late pregnancy to reduce neonatal transmission. Once ACV has been detected in breast milk, caution is advised when using it in nursing mothers (Sawleshwarkar & Dwyer, 2015) .
Penciclovir and Famciclovir
After intracellular uptake, 9-[4-hydroxy-3-(hydroxymethyl)butyl] guanine, known as penciclovir (PCV), is monophosphorylated by virally encoded TK and, subsequently, converted to penciclovir-triphosphate (PCV-TP) by cell enzymes, being then able to act as a viral DNA polymerase inhibitor. At clinical relevant levels, PCV-TP has no substantial effect upon cell DNA polymerase, thereby minimizing side effects to the host (Perry & Wagstaff, 1996) .
The PCV mechanism of action is similar to that described for ACV and, although PCV exhibits lower affinity for viral DNA polymerase, it has a longer intracellular half-life than ACV (Perry & Wagstaff, 1996) .
Famciclovir, known as 2-[2-(2-amino-9H-purin-9-yl)ethyl]-1,3-propanediol dictate, is an orally administered pro-drug of the antiviral agent PCV, and it is converted, in vivo, to PCV (SmithKline Beecham, 1997) . PCV is subsequently phosphorylated to PCV-TP, thus inhibiting the DNA polymerase of susceptible virus (Zachary, 2015b) .
PCV and FCV are active against HSV virus types 1 and 2 (HSV-1, HSV-2) and VZV. In vitro, PCV also presents activity against Epstein-Barr virus (EBV) (Perry & Wagstaff, 1996) . Mechanisms of resistance to PCV are similar to those described for ACV (Zachary, 2015b) .
The bioavailability of orally administered FCV is of 77%, indicating that FCV is well absorbed (Vere . Prompt first-pass metabolism in the intestine and liver results in conversion to PCV. Food intake has no clinically important effect on PCV plasma levels (Perry & Wagstaff, 1996) . Once it has a prolonged intracellular half-life, PCV-TP requires less frequent dosing when compared to ACV (Perry & Wagstaff, 1996; Zachary, 2015b) .
FCV excretion is primarily renal and dose reduction is recommended in patients with impaired renal function (creatinine clearance < 60 mL/min) (Perry & Wagstaff, 1996 ; SmithKline Beecham, 1997).
Ganciclovir and Valganciclovir
Ganciclovir (GCV) was the first antiviral drug approved for treating cytomegalovirus (CMV) infection and it is widely used in immunocompromised patients with CMV disease, particularly those with HIV/AIDS and recipients of solid organ or hematopoietic stem cell transplantation (HSCT). Valganciclovir (VGCV) is an oral pro-drug that is rapidly hydrolyzed to GCV (Roche, 2009; Zachary, 2014b) .
Ganciclovir (9-[(1,3,-dihydroxy-2-propoxy)methyl] guanine, or DHPG) is an acyclic analogue of the nucleoside guanosine. During infection, a viral kinase encoded by CMV gene UL97 converts intracellular ganciclovir (GCV) to ganciclovir 5'-monophosphate (GCV-MP). After that, cell kinases convert GCV-MP to ganciclovir triphosphate (GCV-TP), which will inhibit viral DNA polymerase (Crumpacker, 1996; Faulds & Heel, 1990) .
GCV and VGCV are used in treating CMV infections. GCV resistance is rare (around 1%), but it can occur in HIV/AIDS patients with CMV retinitis (Roche, 2016) . The main mechanism of resistance to GCV is the lower ability of the viral kinase to form active triphosphate molecules, due to an UL97 gene mutation. Mutations in the viral DNA polymerase have also been reported as being responsible for CMV resistance to GCV, and these virus types can also be resistant to other anti-CMV drugs (Roche, 2016; Tatti et al., 1998; Zachary, 2014b) .
GCV distribution volume is correlated to body weight and to distribution volumes observed in steady states. GCV is excreted, unmodified, in the urine after glomerular filtration (Roche, 2016) .
VGC, a GCV pro-drug, is well absorbed after oral administration, rapidly hydrolyses to GCV in the intestinal wall and liver, and has a bioavailability of approximately 60 per cent (10 times > than GCV) (Roche, 2016) .
Cidofovir
Cidofovir (HPMPC) [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)
cytosine] is an acyclic cytosine phosphate analogue. It is an antiviral drug that needs two phosphorylation steps to be converted to its active metabolite, cidofovir-biphosphate. Cidofovir conversion to cidofovir-monophosphate is not dependent on phosphorylation by viral TK and the biphosphate form competes with the deoxycitidine incorporation on viral DNA. This action causes a delay on DNA chain elongation during its synthesis. The incorporation of two molecules of cidofovir-biphosphate to the DNA chain breaks the DNA synthesis (De Clercq, 2003; Xiong et al., 1997) .
Cidofovir has shown effectiveness and is used off-label against many DNA virus infections, such as HSV, VZV, CMV, human papillomavirus (HPV), poxvirus, adenovirus and polyomavirus (Geerinck et al., 2001; Snoeck et al., 2001) .
CMV isolates resistant to ganciclovir can be susceptible to cidofovir. Cross-resistance between ganciclovir and cidofovir, caused by selective mutations in DNA polymerase gene, as observed after in vitro selection of ganciclovir-resistant CMV isolates. However, this type of resistance was not seen when viral DNA polymerase UL97 gene mutation is present. CMV mutant isolates, selected by foscarnet, did not show cross-resistance with cidofovir (Gilead Sciences, 2010).
Cidofovir has poor oral bioavailability and the drug excretion is renal. Once it has a long intracellular half-life, cidofovir offers a more prolonged antiviral response when compared to its acyclic analogues, such as acyclovir, which shows an antiviral response within a few hours, allowing less frequent dosing (Neyts et al., 1991) .
Pyrophosphate analogue Foscarnet
Foscarnet (trisodium phosphonoformate) is a pyrophosphate analogue and binds reversibly near the pyrophosphate-binding site of the DNA polymerase (or reverse transcriptase), blocking the cleavage of the pyrophosphate moiety from deoxynucleotide triphosphates, halting DNA chain elongation (Wagstaff & Bryson, 1994) . A 100-fold greater foscarnet concentration is required to obtain the inhibition of human DNA polymerase (Wagstaff & Bryson, 1994) .
Foscarnet has antiviral activity against HSV, VZV, CMV and it also inhibits HIV reverse transcriptase (RT). It is used almost exclusively to treat CMV infections (particularly when ganciclovir cannot be employed) in HIV/ AIDS patients or those recipients of solid organ and hematopoietic stem cell transplantation (HSCT) (Biron, 2006) .
Foscarnet resistance is mainly due to point mutations in viral UL54 pol gene and it is considered a second choice therapy in cases of ganciclovir resistance (Stewart, 2010) .
Foscarnet has poor oral bioavailability and is excreted solely by the kidney. Caution is required when treating patients with impaired renal function due to foscarnet toxicity to renal tubules. Patients require adequate hydration and frequent monitoring of creatinine levels (Biron, 2006; Stewart, 2010) .
Neuraminidase inhibitors (NI)
Two drugs of this group are approved for treating influenza virus infection: the oral drug oseltamivir, and the inhalation drug zanamivir.
Oseltamivir and zanamivir
Oseltamivir is commercially available as Tamiflu®, and since 1999 it has been used to treat infections of influenza A and B viruses (Beigel & Bray, 2008) .
Zanamivir was discovered in 1989 and is effective against influenza A and B viruses in children (aged 7 years and over) and adults (Burls et al., 2002) .
Neuraminidase inhibitors (NI) act on the viral neuraminidase protein, blocking the release of viruses from infected host cells and prevents the infection of new host cells. These antiviral agents inhibit all subtypes of neuraminidase enzymes; therefore they are effective against influenza (FLU) viruses A and B. Although the genetic composition of the virus is under constant mutation, the amino acid sequence at the enzyme active site is highly conserved, offering an optimal region for antiviral therapy (Burls et al., 2002; Beigel & Bray, 2008) .
Oseltamivir (ethyl (3R,4R,5S)-4-acetamido-5-amino-3-pentan-3-yloxycyclohexene-1-carboxylate) is a cyclohexene analogue of silica acid (Ferraris et al., 2010) .
Zanamivir ( After oral administration, oseltamivir is rapidly absorbed and metabolized by esterase enzymes present in the gastrointestinal tract, liver and blood. Absorption is slightly affected by food intake but the general bioavailability is not altered (Wattanagoon et al., 2009 ).
Zanamivir has a short plasma half-life, but it can be detected in lungs over 24 hours after single dose inhalation. It should not be used in patients with respiratory diseases (asthma or chronic obstructive pulmonary disease) due to the risk of bronchospasm and impairment of pulmonary function ( Oseltamivir requires a dose adjustment in those patients with low creatinine clearance (< 30 mL/min). Gastrointestinal intolerance (usually less than 1 day) occurs in 5 to 15% of patients treated with oseltamivir, but it rarely (<2%) requires drug interruption (He et al., 1999) . Table 1 
Drugs for the treatment of viral hepatitis
Viral hepatitis is a systemic infection caused by virus, with a liver inflammatory response-based physiopathology and that, despite the important scientific advances, continues among the most common causes of acute and chronic liver disease and may progress over time to fibrosis (scarring of the liver) and cirrhosis (chronic liver failure), which increases the risk of developing hepatocellular carcinoma (Pawlotsky et al., 2015) .
Seeking to increase life expectancy and improve the patient's quality of life, as well as reduce the incidence of infection by hepatitis C virus (HCV), eradicating-virus therapy should be established according to the Clinical Protocol and Therapeutic Guidelines to Hepatitis C and Coinfection 1 , available online at http://www.aids.gov.br/sites/default/files/anexos/ publicacao/2015/58192/pcdt_capa_miolo_09_2015_baixa_pdf_31917.pdf. 
Drugs for the treatment of HIV/AIDS patients
